Curry, Mary A.
Cruz, Rosángel E.
Belter, Lisa T.
Schroth, Mary K.
Jarecki, Jill
Article History
Received: 14 November 2023
Accepted: 2 February 2024
First Online: 2 March 2024
Conflict of Interest
: Jill Jarecki was an employee of Cure SMA at the time of this study and is currently an employee of BioMarin Pharmaceuticals, Inc. Rosángel Cruz was an employee of Cure SMA at the time of this study; the author has nothing to disclose. Mary Curry, Lisa Belter, and Mary Schroth have nothing to disclose.
: Prior to distribution, WIRB-Copernicus Group Institutional Review Board (WCG IRB) determined that the study was exempt from full IRB review and granted a consent waiver. All respondents were informed via the Cure SMA privacy policy that findings may be published. Only aggregate results are included within the manuscript. All procedures performed involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.